Introduction {#s1}
============

Acute myeloid leukemia (AML) is characterized by autonomous proliferation and impaired differentiation of hematopoietic progenitors but is a genetically and phenotypically heterogeneous disease. The development of AML is associated with accumulation of acquired genetic alterations and epigenetic changes in hematopoietic progenitor cells that induces normal hematopoietic progenitor cell to loss the ability of self-renewal and differentiation to various mature cell lineages, to transform into a leukemic stem cell, and to accumulate in bone marrow [@pone.0045760-Huntly1], [@pone.0045760-Jordan1]. In recent years, an increasing number of gene mutations have been identified involved in the pathogenesis of the disease and have been shown to be correlated with prognosis of AML patients [@pone.0045760-Dhner1]. Some gene mutations have been further introduced into the current World Health Organization (WHO) classification [@pone.0045760-Swerdlow1].

U2AF1 (U2AF35), an essential component of the U2 small nuclear ribonucleoprotein auxiliary factor (U2AF), plays an important role in the splicing process in which functional mRNA is generated from pre-mRNA [@pone.0045760-Zamore1], [@pone.0045760-Black1]. The disruption of interactions of several factors involved in the splicing process can cause various types of mutations in an ever increasing number of genes [@pone.0045760-Baralle1]. Recently, somatic mutations in *U2AF1* were discovered in myelodysplastic syndrome (MDS) and mainly occurred in two codons (Ser34 and Q157) [@pone.0045760-Graubert1], [@pone.0045760-Yoshida1]. Patients with *U2AF1* mutations had an increased probability of progression from MDS to AML, however, they had similar overall survival as those with wild-type *U2AF1* [@pone.0045760-Graubert1]. The prognostic impact and clinical characteristics of patients with *U2AF1* mutations in AML are unknown. Thus, in this study we investigated the frequency and prognostic influence of *U2AF1* mutations in a cohort of patients with AML, MDS and chronic myeloid leukemia (CML) patients.

Materials and Methods {#s2}
=====================

Patients\' samples {#s2a}
------------------

This study was approved by the Ethics Committee Board of Affiliated People\'s Hospital of Jiangsu University. Bone marrow aspirates or peripheral blood samples of patients with various hematologic malignancies were collected after informed consent written. The patients included 275 primary AML, 96 primary MDS, 81 CML (61 at chronic phase, 4 at accelerated phase, 16 at blast crisis). These hematological malignancies were diagnosed according to the French-American-British Cooperative Group Criteria and the 2008 World Health Organization proposal [@pone.0045760-Swerdlow1], [@pone.0045760-Bennett1]. Karyotypes were classified according to reported previously [@pone.0045760-Slovak1], [@pone.0045760-Greenberg1]. Bone marrow specimens obtained at the time of complete hematologic remission from three patients (one AML, one RAEB-1 and one RAEB-2) with *U2AF1* mutations at initial diagnosis and peripheral blood from 103 healthy individuals were used as control. The mononuclear cells were separated by density-gradient centrifugation using Ficoll. Subsequently, genomic DNAs were extracted using the Genomic DNA Purification Kit (Gentra, USA) according to the manufacturer\'s instructions.
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###### The clinical and hematopoietic parameters of 13 patients with *U2AF1* mutations.
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  ID    Sex/Age (years)   Diagnosis   WBC (×10^9^/L)   Hemoglobin (g/L)   Platelet (×10^9^/L)          Karyotype          Survival time (months)   *U2AF1* mutation
  ---- ----------------- ----------- ---------------- ------------------ --------------------- ------------------------- ------------------------ ------------------
  1          M/20          AML-M2         130.2              107                  69                      +8                        3                    S34Y
  2          M/76          AML-M1          97.0               40                  33                    No data                     1                   Q157P
  3          F/29          AML-M2          75.1               76                  50                      +8                        1                    S34Y
  4          M/44          AML-M4          3.9                64                  48                      −7                        9                   Q157R
  5          M/60          AML-M2          3.5                54                  30                       N                        6                    S34F
  6          F/80          AML-M2          0.9                56                  31                       N                        5                    S34Y
  7          M/66          AML-M5          37.2               65                  42            1p+,−5,22q+,+mar1,+mar2          No data                 S34Y
  8          M/86          RAEB-1          2.3                43                  31                    No data                     4+                  Q157P
  9          M/31          RAEB-2          1.4                51                  30                       N                        4+                   S34Y
  10         F/31          RCMD-RS         2.6                79                  101               del(5)(q21q34)                  45                   S34F
  11         M/28          RAEB-2          2.4                56                  44                       N                        40                   S34F
  12         M/67          RAEB-1          1.6                66                  130                      N                        22                   S34F
  13         F/40          RCMD-RS         3.0                41                  88                      +8                        1+                   S34Y

M, male; F, female; N, normal;.

Mutation scanning {#s2b}
-----------------

Primers to amplify the coding sequences of *U2AF1* (GenBank NC_000021.8) are listed in [Table S1](#pone.0045760.s010){ref-type="supplementary-material"}. genomic DNA samples were amplified in a final volume of 25 μl containing 1× PCR buffer (Invitrogen, Merelbeke, Belgium), 0.2 mmol/L of each dNTP, 2.5 mmol/L of MgCl~2~, 0.4 μmol/L of both forward and reverse primers, 0.8 μmol/L of oligonucleotide calibrators [@pone.0045760-Qian1], 1× LCgreen Plus (Idaho Technology Inc. Salt Lake City, Utah), and 1 U Taq polymerase (MBI Fermentas, Canada). All PCR amplicons were generated on a 7300 Thermo cycler (Applied Biosystems, Foster City, CA, USA) using the PCR program as follows: an initial denaturation step was started at 95°C for 5 minutes, followed by 40 cycles of denaturation at 94°C for 30 seconds, annealing at melting temperature for 30 seconds, and an extension at 72°C for 30 seconds. Mutation scanning was performed for PCR products using high-resolution melting analysis (HRMA) with the LightScanner^TM^ platform (Idaho Technology Inc. Salt Lake City, Utah) according to the protocol reported previously [@pone.0045760-Lin1].
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###### Distribution of *U2AF1* mutations in AML and MDS.
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                                                     *U2AF1* mutation       Wild-type       *P*
  ------------------------------------------------- ------------------- ----------------- -------
  AML                                                        7                 268        
  Sex, male/female                                          5/2              149/119       0.471
  Median age at diagnosis, years (range)                60 (20--80)        47 (15--93)     0.402
  Median WBC at diagnosis, ×10^9^/L (range)          37.2 (0.9--130.2)    14 (0.5--528)    0.690
  Median hemoglobin at diagnosis, g/L (range)          64 (40--107)       74 (32--147)     0.196
  Median platelets at diagnosis, ×10^9^/L (range)       42 (30--69)        38 (3--447)     0.634
  FAB, no.                                                                                 0.770
   M0                                                        0                  1         
   M1                                                        1                 33         
   M2                                                        4                 106        
   M3                                                        0                 42         
   M4                                                        1                 42         
   M5                                                        1                 33         
   M6                                                        0                 11         
  Karyotype classification                                                                 0.152
   Favorable                                                 0                 72         
   Intermediate                                              4                 145        
   Poor                                                      2                 30         
   No data                                                   1                 21         
  Gene mutations                                                                          
   C-KIT (+/−)                                              0/7              13/255        1.000
   NPM1 (+/−)                                               2/5              20/248        0.100
   FLT3-ITD (+/−)                                           0/7              14/254        1.000
   IDH1/IDH2 (+/−)                                          0/7              12/256        1.000
   DNMT3A (+/−)                                             0/7              14/254        1.000
  MDS                                                        6                 90         
  Sex, male/female                                          4/2               54/36        1.000
  Median age at diagnosis, years (range)                36 (28--86)        60 (20--85)     0.134
  Median WBC at diagnosis, ×10^9^/L (range)           2.4 (1.4--3.0)     2.8 (0.6--82.4)   0.129
  Median hemoglobin at diagnosis, g/L (range)           54 (41--79)       62 (26--128)     0.237
  Median platelets at diagnosis, ×10^9^/L (range)      66 (30--130)       60 (1--1176)     0.745
  WHO, no.                                                                                 0.571
   5q-                                                       0                  3         
   RA/RARS/RT                                                0                 11         
   RCMD/RCMD-RS                                              2                 41         
   RAEB-1                                                    2                 18         
   RAEB-2                                                    2                 17         
  Karyotype classification                                                                 0.386
   Favorable                                                 4                 64         
   Intermidiate                                              1                 16         
   Poor                                                      0                  8         
   No data                                                   1                  2         
  IPSS                                                                                     0.449
   Low                                                       0                  9         
   Int-1                                                     4                 56         
   Int-2                                                     0                 17         
   High                                                      0                  6         
   No data                                                   0                  2         
  Gene mutations                                                                          
   IDH1/IDH2 (+/−)                                          0/6               5/85        
   DNMT3A (+/−)                                             0/6               4/86        

WBC indicates white blood cell count at diagnosis; IPSS, International Prognostic Scoring System; WHO, World Health Organization; FAB, French-American-British classification; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RT, refractory thrombocytopenia; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia with ringed sideroblasts; RAEB, refractory anemia with excess of blasts;.

*FLT3* internal tandem duplication (ITD), *NPM1*, *IDH1*/*IDH2* and *DNMT3A* mutations were detected as reported previously [@pone.0045760-Kottaridis1]--[@pone.0045760-Lin3]. *C-KIT* mutation was also detected using PCR-HRMA.

DNA sequencing {#s2c}
--------------

To confirm HRMA results, DNA sequencing was also performed in all samples identified by HRMA. PCR products were directly sequenced on both strands using an ABI 3730 automatic sequencer.

Statistics {#s2d}
----------

Statistical analysis was performed using the SPSS 13.0 software package (SPSS, Chicago, IL, USA). Pearson Chi-square analysis and Fisher exact test were carried out to compare the difference of categorical variables between patient groups. Mann-Whitney\'s U-test was carried out to compare the difference of continuous variables between patient groups. Survival was analyzed according to the Kaplan-Meier method. For all analyses, a *P*-value of less than 0.05 (two-tailed) was considered statistically significant.

Results and Discussion {#s3}
======================

HRMA could easily distinguish *U2AF1* mutations (S34Y and Q157R) with the sensitivity of 5% in a background of wild-type DNA, higher than that obtained by direct DNA sequencing (10%) ([Figures S1](#pone.0045760.s001){ref-type="supplementary-material"}, [S2](#pone.0045760.s002){ref-type="supplementary-material"}, [S3](#pone.0045760.s003){ref-type="supplementary-material"} and [S4](#pone.0045760.s004){ref-type="supplementary-material"}).

In the cohort of 452 patients with myeloid malignancies, a heterozygous *U2AF1* mutant was found to in 13 cases with AML or MDS, but in none with CML. The representative results of HRMA and directing sequencing of *U2AF1* mutations in AML and MDS were presented in [Figures S5](#pone.0045760.s005){ref-type="supplementary-material"}, [S6](#pone.0045760.s006){ref-type="supplementary-material"}, [S7](#pone.0045760.s007){ref-type="supplementary-material"} and [S8](#pone.0045760.s008){ref-type="supplementary-material"}. The clinical characteristics of all patients with *U2AF1* mutations were shown in [Table 1](#pone-0045760-t001){ref-type="table"}. *U2AF1* mutation, positive in the bone marrow samples from three individuals (case 4,11 and 12, [Table 1](#pone-0045760-t001){ref-type="table"}) at initial diagnosis, disappeared after the first complete remission. Furthermore, *U2AF1* mutation was not present in all healthy controls. These results support the somatic nature of *U2AF1* mutations.

Heterozygous *U2AF1* mutations were found in 7 (2.5%) of 275 AML patients ([Table 1](#pone-0045760-t001){ref-type="table"}), including 3 S34Y, 2 S34F and 2 Q157 (1 Q157P and 1 Q157R) mutations. There were no difference in sex, age, blood parameters, FAB subtypes, and karyotype classification between cases with and without mutations (*P*\>0.05, [Table 2](#pone-0045760-t002){ref-type="table"}). Makishima et al reported higher occurrence (9.1%, 5/55) of *U2AF1* mutations in primary AML [@pone.0045760-Makishima1]. A larger cohort of Yoshida et al revealed 2% (3/151) of *U2AF1* mutations in Japanese AML population [@pone.0045760-Yoshida1]. *U2AF1* mutations mainly occurred in the FAB subtypes of M1, M2, M4 and M5 [@pone.0045760-Yoshida1], [@pone.0045760-Makishima1]. Interestingly, all five *U2AF1* mutations found by Makishima et al occurred in cytogenetically abnormal AML, including two cases with monosomy 7 [@pone.0045760-Makishima1]. However, two cases with *U2AF1* mutations were identified with trisomy 8 besides one with monosomy 7 in our AML group. More patients should be investigated to determine the association of *U2AF1* mutations with karyotypes. *C-KIT*, *FLT3-ITD*, *NPM1*, *IDH1*/*IDH2* and *DNMT3A* mutations were also detected. Among the patients with *U2AF1* mutations, only two cases had *NPM1* mutation. There was no significant association of *U2AF1* mutation with other molecular alterations ([Table 2](#pone-0045760-t002){ref-type="table"}).

Follow-up data were obtained for 150 AML patients. There was no significant difference in complete remission rate between patients with and without *U2AF1* mutation (57.1% vs 72.9%, *P* = 0.398). The median follow-up duration of the patients was 7 months (range, 1--73 months). M3 subtype was excluded from survival analysis due to different therapy and prognosis. The estimated 50% survival time of the remaining 126 patients was 7 months. The overall survival (OS) of AML patients with *U2AF1* mutation (median 3 months, 95% confidence interval 0--7.8 months) was shorter than those without mutation (median 7 months, 95% confidence interval 4.8--9.2 months) (*P* = 0.035, [Figure S9](#pone.0045760.s009){ref-type="supplementary-material"}). However, there was no difference in disease-free survival between the patients with and without *U2AF1* mutation. Two patients with *U2AF1* mutation died early after initial diagnosis due to central nervous system involvement and sepsis respectively. Furthermore, a multivariate analysis for outcomes could not be performed because of the small sample size of patients with mutations. A larger cohort from a clinical trial will be needed to definitively address the effect of *U2AF1* mutations on outcomes.

6 (6.3%) MDS cases were identified with heterozygous *U2AF1* mutations (3 S34F, 2 S34Y, and 1Q157P) ([Table 1](#pone-0045760-t001){ref-type="table"}). No significance in sex, age, blood parameters, WHO subtypes, and IPSS classification was observed between MDS patients with and without *U2AF1* mutations (*P*\>0.05, [Table 2](#pone-0045760-t002){ref-type="table"}). 7.3%--8.8% of *U2AF1* mutations have been reported in primary MDS recently [@pone.0045760-Graubert1], [@pone.0045760-Yoshida1], [@pone.0045760-Makishima1]--[@pone.0045760-Damm1]. All 72 *U2AF1* mutations in MDS including ours, which could be almost found in each FAB or WHO subtype, exclusively occurred at the highly conserved sites of exon S34 and Q157 with a rare exception of A26V, E159, or R156H mutation in three subjects [@pone.0045760-Yoshida1], [@pone.0045760-Lin2], [@pone.0045760-Lin3]. Significant association of *U2AF1* mutations has not been identified with specific karyotypes. Although Damm et al [@pone.0045760-Damm1] found that the association of del20q with *U2AF1* mutation, no *U2AF1* mutation was observed in all four cases with del20q in our group. Survival analysis was performed in 76 MDS cases with follow-up information. No difference in OS was observed between patients with and without *U2AF1* mutations (*P* = 0.821, Figure S9). The impact of *U2AF1* mutations on clinical outcome has been controversial in MDS [@pone.0045760-Graubert1], [@pone.0045760-Makishima1], [@pone.0045760-Thol1]. Although Makishima et al considered *U2AF1* mutation as a factor predictive for shorter survival [@pone.0045760-Makishima1], other three studies did not find the association of *U2AF1* mutation with prognosis [@pone.0045760-Graubert1], [@pone.0045760-Thol1], [@pone.0045760-Damm1]. More cases with *U2AF1* mutations should be further studied to determine its prognostic relevance.

The definite role of *U2AF1* in the cancer pathogenesis has not been known. *U2AF1* mutation induces abnormal global RNA splicing which has been described in a wide variety of cancers [@pone.0045760-Grosso1]--[@pone.0045760-Pajares1]. Reduced expression of *U2AF1* was found in pancreatic cancer cells and correlated with mis-splicing of the cholecystokinin-B/gastrin receptor mRNA [@pone.0045760-Ding1]. Additionally, knockdown of *U2AF1* reduces cell proliferation, induces G2/M arrest, and enhances apoptosis [@pone.0045760-Pacheco1]. Moreover, a recent study demonstrated that S34F mutant had the same effect as *U2AF1* downregulation [@pone.0045760-Yoshida1]. These results suggest that *U2AF1* mutant leads to loss of function and contributes to ineffective hematopoiesis and the cytopenias seen in MDS. Furthermore, subjects with *U2AF1* mutations were not restricted to a particular WHO subtypes, which indicates *U2AF1* mutation should be an early, initial genetic event in MDS.

In summary, mutations in *U2AF1* occur in patients with AML at a low frequency and are associated with a negative prognosis in AML which will require confirmation in a larger cohort.
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**Results of a dilution series of S34Y** ***U2AF1*** **mutant in a background of wild-type DNA detected by HRMA.** 1: 0%, 1% and 2% mutant; 2: 5% mutant; 3: 10% mutant; 4: 25% mutant; 5: 50% mutant; 6: 100% mutant. A: normalized melting peaks; B: normalized difference curves. Mutated S34Y *U2AF1* was identified by HRMA at the maximal sensitivity of 5%. Although the shapes were similar, homozygous mutants could be distinguished from wild-type amplicons by Tm shift.
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Click here for additional data file.

###### 

**Results of a dilution series of S34Y** ***U2AF1*** **mutant in a background of wild-type DNA detected by DNA sequencing.** The maximal sensitivity of 10% was obtained. Arrow showed the mutation site.

(DOC)
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Click here for additional data file.
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**Results of a dilution series of Q157R** ***U2AF1*** **mutant in a background of wild-type DNA detected by HRMA.** 1: 0%, 1% and 2% mutant; 2: 5% mutant; 3: 10% mutant; 4: 25% mutant; 5: 50% mutant; 6: 100% mutant. A: normalized melting peaks; B: normalized difference curves.

(DOC)
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Click here for additional data file.

###### 

**Results of a dilution series of Q157R** ***U2AF1*** **mutant in a background of wild-type DNA detected by DNA sequencing.** The maximal sensitivity of 10% was obtained. Arrow showed the mutation site.

(DOC)
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Click here for additional data file.

###### 

**HRMA screening of S34** ***U2AF1*** **mutations in MDS patients.** Grey lines represent wild-type S34 *U2AF1*; Blue line represents heterozygous S34F mutant in one MDS case; Orange line represents heterozygous S34Y mutant in one MDS case.

(DOC)
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Click here for additional data file.
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**Sequencing results of S34** ***U2AF1*** **mutations in AML and MDS patients.** A: heterozygous S34Y mutation (TCT→TAT); B: heterozygous S34F mutation (TCT→TTT). Arrow denotes mutation site.

(DOC)
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Click here for additional data file.
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**HRMA screening of Q157** ***U2AF1*** **mutations in AML patients.** Grey lines represent wild-type Q157 *U2AF1*; Red lines represent heterozygous Q157P mutant in one AML case.

(DOC)
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Click here for additional data file.
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**Sequencing results of Q157** ***U2AF1*** **mutations.** A: heterozygous Q157P mutation (CAG→CCG) in one case with AML-M1; B: heterozygous Q157R mutation (CAG→CGG) in one case with AML-M4; Arrow denotes mutation site.

(DOC)
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Click here for additional data file.
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**Overall survival of AML or MDS patients divided according to U2AF1 mutation status at diagnosis.** A: AML; B: MDS.
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Click here for additional data file.
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**The sequences of primers used in PCR for HRMA or direct sequencing.**
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Click here for additional data file.
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